FrancophonIA/ELRC3.0 huggingface dataset:
English: Clopidogrel 1A Pharma is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Maltese: Clopidogrel 1A Pharma jittieħed biex inaqqas ir-riskju li emboli tad-demm (trombi) jifformaw flarterji mwebbsin (arterji), proċess imsejjaħ aterotrombosi, li jista' jwassal għal konsegwenzi aterotrombotiċi (bħal puplesija, attakk tal-qalb, jew mewt).
English: The active metabolite of Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Maltese: Il-metabolit attiv ta' Clopidogrel jimpedixxi b'mod selettiv l-irbit ta' adenosine diphosphate (ADP) mar-riċettur tal-plejtlits P2Y12 u l-attivazzjoni suċċessiva talkumpless ta' glikoproteina GPIIb/IIIa bl-intervent ta' ADP, u b'hekk jimpedixxi l-aggregazzjoni talplejtlits.
English: After repeated doses of 75 mg Clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.
Maltese: Wara dożi ripetuti ta' 75 mg Clopidogrel kuljum għal 10 ijiem f'pazjenti b'indeboliment epatiku sever, l-inibizzjoni tal-aggregazzjoni tal-plejtlits kawża tal-ADP kien simili għal dak osservat f'suġġetti b'saħħithom.
English: At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of Clopidogrel was also reported in rat and baboon.
Maltese: F'dożi għolja ħafna, ġiet irrapurtata tollerabilita` baxxa fiż-żaqq (gastrite, erożjonijiet gastriċi u/jew rimettar) ta' Clopidogrel fil-firien u l-babwini.
English: Thrombolytics: the safety of the concomitant administration of Clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Maltese: Trombolitiċi: is-sigurta` tat-teħid flimkien ta' Clopidogrel, sustanzi trombolitiċi speċifiċi għall-fibrina jew li m'humiex u heparins ġiet eżaminata f'pazjenti li kellhom infart mijokardijaku akut.
English: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): Clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Maltese: Bis-segment mhux ST elevat (anġina instabbli jew infart mijokardijaku mhux-mewġa-Q): ilkura bi Clopidogrel għandha tinbeda b'doża waħda qawwija tal-bidu ta' 300 mg u titkompla b'75 mg darba kuljum (b'acetylsalicylic acid (ASA) 75 mg-325 mg kuljum).
English: Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence
Maltese: Ulċera gastrika u ulċera dwodenali, gastrite, rimettar, tqalligħ, stitikezza, gas flistonku
English: Published frequencies for the common CYP2C19 phenotypes and genotypes are listed in the table below.
Maltese: Frekwenzi ppubblikati għall-fenotipi u l-ġenotipi CYP2C19 komuni huma elenkati fit-tabella ta' hawn taħt.
English: • Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
Maltese: - Bis-segment mhux ST elevat (anġina instabbli jew infart mijokardijaku mhux-mewġaQ), li jinkludu pazjenti fi proċess li titpoġġa stent wara intervent koronarju perkutaneju, flimkien ma' acetylsalicylic acid (ASA).
English: This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.
Maltese: Dan kien konsistenti filfirxa ta' sottogruppi ta' pazjenti migbura skond linja bażi ta' karatteristiċi u t-tip ta' terapija fibrinolitika jew bil-heparin.
English: Patients were randomised to Clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
Maltese: Il-pazjenti kienu randomised għal Clopidogrel 75 mg/jum jew ASA 325 mg/jum, u ġew osservati għal bejn sena u 3 snin.
English: • uncommon: affects 1 to 10 users in 1,000
Maltese: • mhux komuni: jaffettwaw minn 1 sa 10 utenti minn kull 1,000
English: After repeated doses of 75 mg Clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of Clopidogrel per day.
Maltese: Wara dożi ripetuti ta' 75 mg ta' Clopidogrel kuljum, f'persuni b'mard sever tal-kliewi (tneħħija talkreatinina minn 5 sa 15 ml/min), l-inibizzjoni ta' l-agreggrazzjoni tal-plejtlets indotti minn ADP kien iktar baxx (25%) minn dak osservat f'persuni f'saħħithom, madankollu it-titwil fil-ħin tad-dmija kien simili għal dak osservat f'persuni f'saħħithom li kienu qed jingħataw 75 mg ta' Clopidogrel kuljum.Barra minn hekk, it-tolleranza klinika kienet tajba fil-pazjenti kollha.
English: In CLARITY and one of the cohort studies (n = 765; Trenk), cardiovascular event rates did not differ significantly by genotype.
Maltese: F'CLARITY u f'wieħed mis-sett ta' studji (n=765; Trenk), ir-rati ta' avvenimenti kardjovaskulari ma varjawx b'mod sinifikanti minħabba l-ġenotip.
English: Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in the way things taste.
Maltese: -Effetti sekondarji rari ħafna: suffejra; uġigħ addominali qawwi flimkien ma' jew mingħajr uġigħ fid-dahar; deni, diffikultajiet finnifs kultant assoċjati mas-sogħla; reazzjonijiet allerġiċi ġeneralizzati; nefħa fil-ħalq; infafet fil-ġilda; reazzjoni allerġika fil-ġilda; infjammazzjoni tal-ħalq (stomatite); tnaqqis fil-pressjoni tad-demm; konfużjoni; alluċinazzjonijiet; uġigħ fil-ġogi; uġigħ muskolari; tibdiliet fil-mod ta' kif jintegħmu laffarijiet.
English: Thrombocytopenia, leucopenia, eosinophilia
Maltese: Castor oil, idroġenat
English: After single and repeated oral doses of 75 mg per day, Clopidogrel is rapidly absorbed.
Maltese: Wara doża orali waħda u ripetuta ta' 75 mg kuljum, Clopidogrel kien assorbit b'rata mgħaġġla.
English: The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of Clopidogrel.
Maltese: Il-karatteristiċi farmakokinetiċi ta' digoxin jew theophylline ma ġewx modifikati bl-amministrazjoni flimkien ma' Clopidogrel.
English: - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Maltese: - Infart mijokardijaku akut b'segment ST elevat, flimkien ma' ASA f'pazjenti ittrattati bilmediċini u eliġibbli għat-terapija trombolitika
English: If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel 1A Pharma in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Maltese: Jekk ħassejt uġigħ qawwi f'sidrek (anġina mhux stabbli jew attakk tal-qalb), jista' jingħatalek Clopidogrel 1A Pharma flimkien ma' acetylsalicylic acid, sustanza inkorporata f'ħafna mediċini użati biex itaffu l-uġigħ u jnaqqsu d-deni.
English: The safety and efficacy of Clopidogrel have been evaluated in 4 double-blind studies involving over 80,000 patients: the CAPRIE study, a comparison of Clopidogrel to ASA, and the CURE, CLARITY and COMMIT studies comparing Clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy.
Maltese: Is-sigurtà u l-effikaċja ta' Clopidogrel kienu evalwati f'4 studji double blind li involvew 'il fuq minn 80,000 pazjent: fl-istudju CAPRIE, paragun ta' Clopidogrel ma' ASA, u fl-istudji CURE, CLARITY u COMMIT kienu mqabblin Clopidogrel mal-plaċebo, fejn iż-żewġ prodotti mediċinali ngħataw flimkien ma' ASA u terapija oħra li soltu tingħata.
English: After a single oral dose of 75 mg, Clopidogrel has a half-life of approximately 6 hours.
Maltese: Wara doża orali waħda ta' 75mg, Clopidogrel għandu l-half-life bejn wieħed u ieħor ta' 6 sigħat.
English: BEFORE YOU TAKE CLOPIDOGREL 1A PHARMA
Maltese: X'fih Clopidogrel 1A Pharma
English: In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that Clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring Clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Maltese: Partikularment, f'analiżi post-hoc f' 2172 pazjenti (17% tal-popolazzjoni kollha CURE) li kellhom stent impoġġija (Stent-CURE), id-data wriet li Clopidogrel, imqabbel ma plaċebo, wera RRR sinifikanti ta' 26.
English: A number of other clinical studies have been conducted with Clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Maltese: Prodotti mediċinali oħrajn: Saru numru ta' studji kliniċi oħra bi Clopidogrel u prodotti mediċinali oħra li ngħataw flimkien biex tiġi investigata l-possibilita` ta' interazzjonijiet farmakodinamiċi u farmakokinetiċi.
English: To date, the impact of CYP2C19 genotype on the pharmacokinetics of the active metabolite of Clopidogrel has been evaluated in 227 subjects from 7 reported studies.
Maltese: S'issa, l-impatt tal-ġenotip CYP2C19 fuq il-farmakokinetika tal-metabolit attiv ta' Clopidogrel ġie evalwat f'227 suġġett minn 7 studji li ġew irrapportati.
English: Teл.
Maltese: Deni
English: Clopidogrel is extensively metabolised by the liver.
Maltese: Metaboliżmu Clopidogrel jiġi mmetabolizzat b'mod estensiv mil-fwied.
English: Clopidogrel 1A Pharma 75 mg film-coated tablets Clopidogrel
Maltese: Clopidogrel 1A Pharma 75 mg pilloli miksija b'rita Clopidogrel
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of Clopidogrel (as besilate).
Maltese: Kull pillola miksija b'rita fiha 75 mg ta' Clopidogrel (bħala besilate).
English: In another study it was shown that administering Clopidogrel and omeprazole 12 hours apart did not prevent their interaction that is likely to be driven by the inhibitory effect of omeprazole on CYP2C19.
Maltese: Fi studju ieħor deher li l-amministrazzjoni ta' Clopidogrel u omeprazole 12-il siegħa il-bogħod minn xulxin ma jipprevjenux interazzjoni tagħhom li x'aktarx li tiġi mill-effett inibitorju ta' omeprazole fuq CYP2C19.
English: Other side effects reported with Clopidogrel are: -Common side effects:
Maltese: Effetti oħra li ġew irrappurtati bi Clopidogrel huma:
English: Other concomitant therapy: Since Clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of Clopidogrel.
Maltese: Peress li parti mill-metaboliżmu ta' Clopidogrel għall-metabolit attiv tiegħu jsir minn CYP2C19, huwa mistenni li l-użu tal-prodotti mediċinali li jinibixxu l-attività ta' din l-enzima jwasslu għal tnaqqis fillivell tal-metabolit attiv ta' Clopidogrel.
English: Important information about some of the ingredients of Clopidogrel 1A Pharma: Clopidogrel 1A Pharma contains hydrogenated castor oil which may cause stomach upset or diarrhoea.
Maltese: Bħal kull mediċina oħra, Clopidogrel 1A Pharma jista' jkollu effetti sekondarji, għalkemm ma jidhrux fuq kulħadd.
English: Children and adolescents Clopidogrel 1A Pharma is not intended for use in children or adolescents.
Maltese: Tfal u adolexxenti Clopidogrel 1A Pharma m'għandux jingħata lit-tfal jew lill-adolexxenti.
English: Acetylsalicylic acid (ASA): ASA did not modify the Clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but Clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
Maltese: It-teħid flimkien ma' heparin ma kellu l-ebda effett fuq l-inibizzjoni ta' l-aggregazzjoni tal-plejtlets indott minn Clopidogrel.
English: Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
Maltese: Sabiex jipproduċi l-metabolit attiv li jimpedixxi l-aggregazzjoni tal-plejtlits, Clopidogrel irid jiġi mmetabolizzat mill-enzimi CYP450.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel 1A Pharma 75 mg film-coated tablets
Maltese: TAL-PRODOTT MEDIĊINALI Clopidogrel 1A Pharma 75 mg pilloli miksija b'rita
English: Data from the CAPRIE study indicate that phenytoin and tolbutamide can be safely co-administered with Clopidogrel.
Maltese: Tagħrif mill-istudju CAPRIE jindika li phenytoin u tolbutamide jistgħu jiġu amministrat b'sigurta` flimkien ma' Clopidogrel.
English: heparin.
Maltese: Vertigo.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel 1A Pharma 75 mg film-coated tablets Clopidogrel
Maltese: TAL-PRODOTT MEDIĊINALI Clopidogrel 1A Pharma 75 mg pilloli miksija b'rita Clopidogrel
English: See leaflet for further information.
Maltese: U INDIRIZZ TAD-DETENTUR TA' L-AWTORIZZAZZJONI GĦAT-TQEGĦID
English: As with other antiplatelet agents, Clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
Maltese: Bħal fil-każ ta' sustanzi oħra kontra l-plejtlets, Clopidogrel għandu jintuża b'kawtela f'pazjenti li jista' jkollhom riskju ta' iktar dmija minn trawma, operazzjoni jew kundizzjonijiet patoloġiċi oħra u pazjenti li jkunu qed jirċievu l-kura b'ASA, heparin, inibituri ta' glycoprotein IIb/IIIa jew mediċini kontra l-infjammazzjoni li m'humiex sterojdi (NSAIDs) li jinkludu l-inibituri ta' Cox-2.
English: Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of Clopidogrel, sometimes after a short exposure.
Maltese: Ġiet irrapurtata Purpura Trombotika Tromboċitopenika (TTP) b'mod rari ħafna wara l-użu ta' clopidrogel, xi kultant wara espożizzjoni qasira.
English: • You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘POSSIBLE SIDE
Maltese: Għandek ukoll tgħid lit-tabib tiegħek minnufih jekk tiżviluppa kundizzjoni medika (magħrufa wkoll bħala Purpura Trombotika Tromboċitopenika jew TTP) li tinkludi deni u tbenġil taħt il-ġilda li jidher bħal tikek ħomor irqaq, flimkien ma' jew mingħajr għeja kbira mhux spjegata, konfużjoni, sfurija tal-ġilda jew ta' l-għajnejn (suffejra) (ara sezzjoni 4
English: No effect on hepatic metabolising enzymes was observed in humans receiving Clopidogrel at the therapeutic dose.
Maltese: Ma ġiex osservat effett fuq l-enzimi metabolizzanti tal-fwied fi bnedmin li kienu qed jingħataw Clopidogrel b'doża terapewtika.
English: The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months (Clopidogrel: 9.6%; placebo: 6.6%), 1-3 months (Clopidogrel: 4.5%; placebo: 2.3%), 3-6 months (Clopidogrel: 3.8%; placebo: 1.6%), 6-9 months (Clopidogrel: 3.2%; placebo: 1.5%), 9-12 months (Clopidogrel: 1.9%; placebo: 1.0%).
Maltese: 9.6 %; plaċebo: 6.6 %), 1 - 3 xhur (Clopidogrel: 4.5 %; plaċebo:
English: EMA/546473/2014 EMEA/H/C/002754
Maltese: EMEA/H/C/002754
English: The full EPAR and risk management plan summary for Triumeq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: After 48 weeks, 88% of the patients given the combination found in Triumeq (364 out of 414) responded to treatment, compared with 81% of the patients who were given Atripla (338 out of 419).
Maltese: Wara 48 ġimgħa, 88% tal-pazjenti li ngħataw il-kombinazzjoni li tinstab fi Triumeq (364 minn 414) irrispondew għall-kura, meta mqabbel ma' 81% tal-pazjenti li ngħataw Atripla (338 minn 419).
English: Other information about Triumeq
Maltese: Informazzjoni oħra dwar Triumeq
English: This is a summary of the European public assessment report (EPAR) for Triumeq.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Triumeq.
English: Triumeq is available as tablets (50 mg dolutegravir / 600 mg abacavir /300 mg lamivudine) and the recommended dose is one tablet a day, taken with or without food.
Maltese: Triumeq huwa disponibbli bħala pilloli (50 mg dolutegravir / 600 mg abacavir /300 mg lamivudine) u d-doża rakkomandata hija pillola waħda kuljum, meħuda bi jew mingħajr l-ikel.
English: The combination of dolutegravir, abacavir and lamivudine (as found in Triumeq) was evaluated in one main study involving 833 previously untreated patients.
Maltese: Il-kombinazzjoni ta' dolutegravir, abacavir u lamivudine (kif tinstab fi Triumeq) ġiet evalwata fi studju ewlieni wieħed li involva 833 pazjent li qatt ma ġew ikkurati qabel.
English: In patients taking some of the components of Triumeq, certain serious side effects have been seen including hypersensitivity (allergic).
Maltese: F'pazjenti li jieħdu xi komponenti ta' Triumeq, dehru ċerti effetti sekondarji serji inkluż sensittività eċċessiva (allerġija).
English: Triumeq is an antiviral medicine used to treat patients with human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).
Maltese: Triumeq huwa mediċina antivirali li tintuża għall-kura ta' pazjenti bil-virus ta' immunodefiċjenza umana (HIV), il-virus li jikkawża s-sindromu ta' immunodefiċjenza akkwistata (AIDS).
English: The CHMP also noted that giving the combination of dolutegravir, abacavir and lamivudine as a single tablet is an additional treatment option for patients with HIV infection and without the HLA-B (type 5701) gene.
Maltese: Is-CHMP innota wkoll li l-għoti ta' kombinazzjoni ta' dolutegravir, abacavir u lamivudine bħala pillola waħda huwa alternattiva ta' kura addizzjonali għal pazjenti b'infezzjoni tal-HIV u mingħajr il-ġene HLAB (tip 5701).
English: All three active substances in Triumeq are already available in the European Union (EU) as singlecomponent medicines: abacavir has been authorised as Ziagen since 1999, lamivudine as Epivir since 1996, and dolutegravir as Tivicay since January 2014.
Maltese: It-tliet sustanzi attivi fi Triumeq huma diġà disponibbli fl-Unjoni Ewropea (UE) bħala mediċini b'komponent wieħed: abacavir ilu awtorizzat bħala Ziagen mill-1999, lamivudine bħala Epivir mill1996, u dolutegravir bħala Tivicay minn Jannar 2014.
English: Triumeq contains three active substances: dolutegravir, abacavir and lamivudine.
Maltese: Triumeq fih tliett sustanzi attivi: dolutegravir, abacavir u lamivudine.
English: Why is Triumeq approved?
Maltese: Għaliex ġie approvat Triumeq?
English: The other two active substances, abacavir and lamivudine, are nucleoside reversetranscriptase inhibitors (NRTIs).
Maltese: Iż-żewġ sustanzi attivi l-oħrajn, abacavir u lamivudine, huma inibituri tar-reverse-transcriptase tan-nukleoside (NRTIs).
English: One of the active substances in Triumeq, dolutegravir, is an integrase inhibitor.
Maltese: Waħda mis-sustanzi attivi fi Triumeq, dolutegravir, hija inibitur tal-integrase.
English: It is used in patients from 12 years of age and weighing at least 40 kg.
Maltese: Jintuża f'pazjenti milletà ta' 12-il sena u li jiżnu ta' lanqas 40 kg.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Triumeq on 1 September 2014.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Triumeq fl-1 ta' Settembru 2014.
English: Regarding Triumeq's safety profile, this was expected to be similar to the safety profile of the single components and comparable to that of other HIV treatments.
Maltese: Rigward il-profil ta' sigurtà ta' Triumeq, dan kien mistenni jkun simili għall-profil ta' sigurtà tal-komponenti singoli u komparabbli ma' dak ta' kuri oħrajn tal-HIV.
English: In addition, the company that markets Triumeq will provide educational material for healthcare professionals expected to prescribe Triumeq that addresses the risk of abacavir-associated hypersensitivity.
Maltese: Barra minn hekk, il-kumpanija li tqiegħed Triumeq fis-suq sejra tipprovdi materjal edukattiv għallprofessjonisti tal-kura tas-saħħa li mistennija jippreskrivu Triumeq, li jindirizza r-riskji ta' sensittività eċċessiva assoċjata ma' abacavir.
English: Triumeq must not be used together with dofetilide, a medicine used to control cardiac arrhythmia (unstable heartbeat).
Maltese: Triumeq ma għandux jintuża flimkien ma' dofetilide, mediċina li tintuża fil-kontroll ta' arritmija kardijaka (taħbit tal-qalb instabbli).
English: The combination of abacavir and lamivudine has been authorised as Kivexa since 2004.
Maltese: Il-kombinazzjoni ta' abacavir u lamivudine ilha awtorizzata bħala Kivexa mill-2004.
English: The most common side effects with Triumeq (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), headache, nausea (feeling sick), diarrhoea and fatigue (tiredness).
Maltese: L-effetti sekondarji l-aktar komuni bi Triumeq (li jistgħu jaffettwaw aktar minn 1 minn kull 10) huma insomnija (diffikultà biex torqod), uġigħ ta' ras, tqalligħ (tħossok imdardar/imdardra), dijarea u għeja.
English: What are the risks associated with Triumeq?
Maltese: X'inhuma r-riskji assoċjati ma' Triumeq?
English: How does Triumeq work?
Maltese: Kif jaħdem Triumeq?
English: Patients were either given the Triumeq combination or a different three-drug combination (Atripla) that did not include an integrase inhibitor.
Maltese: Il-pazjenti jew ingħataw il-kombinazzjoni Triumeq jew kombinazzjoni oħra bi tliet mediċini differenti (Atripla) li ma kinitx tinkludi inibitur tal-integrase.
English: This is an antiviral medicine that blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
Maltese: Din hija mediċina antivirali li timblokka enzima msejħa integrase li hija meħtieġa mill-virus tal-HIV biex jagħmel kopji ġodda tiegħu nnifsu fil-ġisem.
English: They both work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Maltese: It-tnejn jaħdmu b'modi simili billi jimblukkaw lattività ta' reverse transcriptase, enzima prodotta mill-HIV li tippermettilu jinfetta ċelloli u jagħmel iktar virusijiet.
English: How is Triumeq used?
Maltese: Kif jintuża Triumeq?
English: The main measure of effectiveness was the response rate, which was the proportion of patients with a reduction of the levels of virus in the blood (viral load) to fewer than 50 copies of HIV RNA per ml.
Maltese: Il-kejl ewlieni tal-effikaċja kien ir-rata tar-rispons, li kienet il-proporzjon ta' pazjenti bi tnaqqis tal-livelli tal-virus f'demmhom (tagħbija virali) għal inqas minn 50 kopja ta' RNA tal-HIV kull ml.
English: A risk management plan has been developed to ensure that Triumeq is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Triumeq jintuża bl-aktar mod sigur possibbli.